In controlled pre-clinical and laboratory settings, Retatrutide has been studied across a wide range of metabolic, endocrinological, and physiological research applications: Triple Incretin Receptor Research Retatrutides defining research application is the simultaneous activation of GLP-1R, GIPR, and GCGR enabling researchers to study the combined tri-agonist incretin effect, examine the distinct contribution of each receptor to overall metabolic outcomes, and explore the additive and synergistic interactions between all three receptor systems in ways no prior compound has allowed
Journal of Clinical Gastroenterology, 56 (4), 331338
Clinical data demonstrates that tirzepatide delivers superior weight loss compared to semaglutide, with SURMOUNT trials showing 22% average body weight reduction versus 16% for semaglutide at comparable efficacy doses
Mil Med Res 7(1):11 Loretelli C et al (2020) Embryonic stem cell extracts improve wound healing in diabetic mice
Its administered as a subcutaneous injection and has been clinically tested for safety and efficacy